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The aim of this study was to investigate proton magnetic resonance spectroscopy metabolite values 
in the medial prefrontal cortex of individuals with euthymic bipolar disorder. The subjects consisted 
of 15 patients with euthymic bipolar disorder type I and 15 healthy controls. We performed proton 
magnetic resonance spectroscopy of the bilateral medial prefrontal cortex and measured levels of 
N-acetyl aspartate, choline and creatine. Levels of these three metabolites in the medial prefrontal 
cortex were found to be lower in patients with bipolar disorder compared with healthy controls. A 
positive correlation was found between illness duration and choline levels in the right medial 
prefrontal cortex. Our study suggests that during the euthymic period, there are abnormalities in 
cellular energy and membrane phospholipid metabolism in the medial prefrontal cortex, and that 
this may impair neuronal activity and integrity. 
 
Key Words 
bipolar disorder; proton magnetic resonance spectroscopy; medial prefrontal cortex; N-asetyl 




(1) N-acetyl aspartate, choline and creatine levels in the medial prefrontal cortex were found to be 
lower in patients with bipolar disorder compared with healthy controls. 
(2) There were no significant differences in N-acetyl aspartate/choline or choline/creatine ratios in 
the medial prefrontal cortex between patients with bipolar disorder and healthy controls. Illness 
duration was positively correlated with choline level in the right medial prefrontal cortex. 
(3) During the euthymic period, abnormalities in cellular energy metabolism and membrane 
phospholipid metabolism were present, and this could compromise neuronal activity and integrity in 
the medial prefrontal cortex. 
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Bipolar disorder is a chronic mood disorder characterized 
by recurrent depressive, manic or mixed attacks. In 
euthymic period, the patients may return to a normal 
mood state, or some residual symptoms may remain. 
Bipolar disorder is cyclical, and it is known that as the 
number of attacks increases, their duration tends to 
decrease[1].  
 
Proton magnetic resonance spectroscopy (1H-MRS) is a 
non-invasive imaging technique that can measure 
biochemical structures and metabolites in tissues and 
present them in a single spectrum. The levels of 
neurochemical compounds containing N-acetyl aspartate 
(NAA), choline (Cho) and creatine (Cr) can be 
determined in vivo. NAA is a compound found in adult 
neurons and is recognized as a marker for neuronal 
integrity, viability and/or function[2]. Cho resonance 
reflects levels of phosphocholine, glycerophosphocholine 
and free choline[3]. It has been suggested that high Cho 
levels result from changes in cell membrane 
phospholipid metabolism and membrane degradation[3]. 
Total Cr, which includes Cr and phosphocreatine, is a 
marker of energy metabolism. The Cr peak is used as a 
reference value because it is stable; 1H-MRS is based on 
the assumption that Cr resonance is constant and is not 
affected by various pathologies[3]. 
 
In bipolar disorder, 1H-MRS studies have reported 
conflicting results. It has been observed that compared 
with healthy control groups, the following changes occur in 
patients with euthymic bipolar disorder: (1) hippocampal 
NAA levels are reduced, but Cho levels are unaffected[4]; 
(2) dorsolateral prefrontal cortical NAA/Cr, NAA/Cho and 
Cho/Cr ratios are decreased[5]; (3) NAA levels have a 
tendency to decrease in the basal ganglia[6]; and (4) NAA 
levels are high in the thalamus[7]. Scherk et al [8] reported 
that hippocampal NAA/Cr levels decrease, but the levels 
in the thalamus and putamen are not different from those 
of healthy controls. In young patients with bipolar 
disorder, a study found a decrease in the NAA level in the 
dorsolateral prefrontal cortex and a link between the 
number of past affective episodes and Cho levels[9]. It 
has been reported that during the first episode, bipolar 
disorder patients show decreased hippocampal NAA/Cr 
and NAA/Cho ratios, and illness severity and NAA levels 
show a correlation[10]. However, it has been observed 
that euthymic bipolar disorder patients do not exhibit 
changes in neurochemical metabolite levels in different 
brain regions, such as the anterior cingulate, frontal 
cortex, dorsolateral prefrontal cortex, parietal cortex, 
temporal cortex or basal ganglia[11-16]. 
 
The medial prefrontal cortex receives mostly 
dopaminergic and serotonergic projections, mainly from 
the thalamus, hypothalamus, amygdala, hippocampus, 
and limbic and medial temporal cortex. It is responsible 
for emotionally and instinctively organized aspects of 
behavior[17]. Patients with medial prefrontal cortical 
damage exhibit dysfunctional social behaviors that 
involve planning, judgement and decision-making. 
Inadequate impulse control, euphoria, increased energy, 
aggression and a tendency toward violence may be 
observed[18-19]. A decrease in ventromedial prefrontal 
cortical grey matter volume was detected in bipolar 
disorder patients with rapid cycling[20]. It is claimed that 
functional abnormalities may be present in the amygdala 
and medial prefrontal cortex in patients with euthymic 
bipolar disorder [21]. However, it was reported that medial 
prefrontal cortical Cho and Cr levels in patients with 
bipolar disorder are not different from those of 
controls[22]. 
 
The number of studies that have investigated medial 
prefrontal cortical neurochemical metabolites in bipolar 
disorder patients is limited. The aim of this study was to 
measure NAA, Cho and Cr levels in the medial prefrontal 





Sociodemographic and clinical characteristics 
Fifteen euthymic bipolar disorder patients and 15 healthy 
controls were included in the study. Demographic and 

















Table 1  Sociodemographic characteristics and clinical 
features of patients with bipolar disorder and healthy 
controls
Variable Bipolar disorder 
patients (n = 15) 
Healthy controls
(n = 15) 
z P 
Age (year) 38.9±9.3 38.7±8.6 0.062 0.950
Gender 
(male/female, n)
 9/6  9/6   
Education level 
(year) 
  9.9±4.5  9.33±3.6 0.462 0.644
Age of illness 
onset (year) 
 25.9±7.9 –   
Illness duration 
(year) 
 12.5±7.0 –   
Number of 
attacks  
  5.6±3.1 –   
Number of 
hospitalizations
  3.4±3.5 –   
 Mann-Whitney U test was used to compare the intergroup difference.
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There was no significant difference between the groups 
in age or education level. Six of the patients were on 
mood-stabilizing drugs and atypical antipsychotics, four 
were on lithium and atypical antipsychotics, two were 
taking only lithium, one was taking mood-stabilizing 
drugs and lithium, one was on mood-stabilizing drugs, 
and one was using atypical antipsychotics and lithium. All 
of the patients were in the remission period, and the 
Hamilton Depression Rating Scale and the Young Mania 
Rating Scale scores were determined to be zero. 
 
Medial prefrontal cortical NAA, Cho and Cr levels in 
bipolar disorder patients 
In bipolar disorder patients, bilateral medial prefrontal 
cortical NAA, Cho and Cr levels were found to be lower 
than in healthy controls (Table 2). No differences were 
detected in NAA/Cr or Cho/Cr ratios between bipolar 





















A positive correlation was detected between illness 
duration and right medial prefrontal cortical Cho levels  
(rs = 0.605 P = 0.017, Spearman’s correlation coefficient). 
No correlation was detected between illness duration 
and other neurochemical metabolites (Table 3). No 
correlation was detected between neurochemical 
metabolite levels and number of attacks or number of 
hospitalizations (Table 3). Left medial prefrontal cortical 
Cr values were found to be significantly lower in patients 
who used lithium (n = 8) compared with those who did 
not (n = 7) (z = 2.459, P = 0.014, Mann-Whitney U test). 
There was no difference in other metabolite levels 
between bipolar disorder patients who used lithium and 
those who did not (right medial prefrontal cortical NAA, 
Cho, Cr, NAA/Cr, Cho/Cr: z = 1.389, 0.985, 0.521, 1.143, 
0.571, respectively; left medial prefrontal cortical NAA, 
Cho, NAA/Cr, Cho/Cr: z = 0.463, 1.389, 0.232, 1.504, 







































Middle-aged patients with a diagnosis of bipolar disorder 
type I who regularly used psychotropic drugs participated 
in the study. Medial prefrontal cortical NAA, Cho and Cr 
levels were found to be lower in patients with euthymic 
bipolar disorder compared with healthy controls. In 
bipolar disorder, it has been reported that NAA, NAA/Cr 
and NAA/Cho are decreased in the frontal cortex and 
dorsolateral prefrontal cortex[5, 23]. Similarly, studies have 
shown reduced prefrontal NAA levels in children with 
bipolar disorder[9, 24]. It was reported that Cho and Cr 
Table 2  Comparison of neurochemical metabolites in the 
medial prefrontal cortex in patients with bipolar disorder 




patients (n = 15) 
Healthy controls 
(n = 15) z P 
NAA     
Right 7 571±2 850 12 138±2 413 3.609 0.000
Left 6 882±1 734 12 269±2 588 4.334 0.000
Cho     
Right 4 597±2 052  6 921±1 533 3.049 0.002
Left 4 319±1 527  7 290±2 067 3.546 0.000
Cr     
Right 4 173±2 191  6 703±1 775 2.987 0.002
Left 3 718±1 213  6 223±1 325 3.961 0.000
NAA/Cr            
Right 1.82±0.39  1.86±0.29 0.346 0.730
Left 1.98±0.48  2.02±0.39 0.601 0.548
Cho/Cr            
Right 1.12±0.38  1.05±0.18 0.046 0.963
Left 1.21±0.39  1.16±0.19 0.104 0.917
The data are expressed as mean ± SD. Mann-Whitney U test was 
used to compare the intergroup difference. NAA: N-acetyl 
aspartate; Cho: choline; Cr: creatine. 
Table 3  Correlation between neurochemical metabolites 
in the medial prefrontal cortex in patients with bipolar 
disorder and duration of illness, as well as number of 
attacks and number of hospitalizations 
Variable Neurochemical metabolite rs P 








 Cr 0.464 0.081
 NAA 0.436 0.104
 Cho/Cr 0.139 0.652
 NAA/Cr 0.055 0.857
Left mPFC Cho 0.431 0.109
 Cr 0.108 0.701
 NAA 0.413 0.126
 NAA/Cr 0.233 0.404
 Cho/Cr 0.445 0.096








  Cr 0.207 0.459
 NAA 0.055 0.847
 Cho/Cr 0.051 0.870
 NAA/Cr 0.337 0.260
 Left mPFC Cho 0.120 0.669
 Cr 0.024 0.933
 NAA 0.231 0.407
 NAA/Cr 0.004 0.990









 Cr 0.036 0.898
 NAA 0.013 0.962
 Cho/Cr 0.057 0.854
 NAA/Cr 0.149 0.627
Left mPFC Cho 0.101 0.720
 Cr 0.170 0.545
 NAA 0.197 0.482
 NAA/Cr 0.227 0.415
 Cho/Cr 0.290 0.294
Spearman’s correlation analysis was used. mPFC: Medial prefrontal 
cortex; Cho: choline; Cr: creatine; NAA: N-acetyl aspartate.  
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levels are decreased in the frontal cortex, basal ganglia 
and hippocampus in bipolar disorder[4, 13, 25]. Frey et al [26] 
determined that dorsolateral prefrontal cortical Cr levels 
were low in unmedicated patients with bipolar disorder. It 
has been proposed that cellular energy and phospholipid 
metabolism are impaired in bipolar disorder patients, and 
that mitochondrial dysfunction occurs. However, some 
studies reported conflicting results for the same or 
different brain regions. A number of studies found 
increased levels of Cho and Cr in the basal ganglia, 
hippocampus, orbitofrontal cortex and thalamus in 
bipolar disorder patients[7, 27-28]. Furthermore, some 
studies found no significant changes in neurochemical 
metabolite levels in the prefrontal cortex, basal ganglia or 
hippocampus in bipolar disorder [14, 16, 29-30]. Normal 
neurochemical metabolite levels reflect healthy neuronal 
function. Our results suggest impaired neuronal viability 
and integrity, as well as abnormalities in membrane 
phospholipid and energy metabolism in the medial 
prefrontal cortex of patients with euthymic bipolar disorder. 
 
The medial prefrontal cortex plays a pivotal role in the 
regulation of emotion and social functioning. There are a 
limited number of studies investigating neurochemical 
metabolites in this brain region. One study found that 
neurochemical metabolite levels, including those of Cho, 
Cr, myo-inositol and NAA, in the medial prefrontal cortex 
are similar in unaffected and affected participants at high 
genetic risk for bipolar disorder and in control 
participants[31]. The conflicting results in this field and the 
limited number of studies make our findings difficult to 
comment on. The patients in our study were followed and 
treated regularly. In our study, none of the patients 
exhibited manic or depressive symptoms. However, we 
did not clinically evaluate medial prefrontal cortical 
functions, such as social function. Further study is 
required to assess social function in more details. 
Studies of bipolar disorder that investigate 
pathophysiology and neurochemistry are increasing in 
number. However, interpreting results is challenging 
because the illness includes depressive, manic and 
euthymic periods, and different brain regions regulate 
mood. It has been reported that the NAA level in the 
frontal cortex is low during manic episodes[32], but that 
NAA, Cho and Cr levels in the dorsolateral prefrontal 
cortex of bipolar disorder patients are similar to that in 
controls[33]. Some researchers evaluate bipolar disorder 
patients in euthymic, depressive and manic episodes 
together[16, 34-37], and some studies include bipolar 
disorder type I and type II patients[16, 28, 35-36]. Clearly, 
there is a need for investigators to standardize the use of 
patient groups to facilitate the comparison of results. 
We detected a positive correlation between illness 
duration and Cho levels in our study; as illness duration 
increased, Cho levels rose. It was reported that there is a 
relationship between Cho levels and the number of 
affective episodes[9]. However, Gallelli et al [38] reported 
that NAA/Cr levels are not related to age, illness duration, 
or lithium and valproate usage. Supposedly, NAA/Cr 
level is not a marker for bipolar disorder. DelBello et al [39] 
investigated the effects of olanzapine treatment on 
medial and lateral prefrontal neurochemical metabolite 
levels in patients who had their first manic attack. A 
significant increase was observed in the prefrontal NAA 
levels of patients who responded to olanzapine. An 
increase in medial and lateral prefrontal Cho levels was 
observed 1 week after olanzapine treatment. It was 
found that in manic patients successfully treated with 
olanzapine, prefrontal cortical neuronal activity and 
functioning tended to increase. The increase in Cho 
levels with treatment was interpreted as an amelioration 
of abnormalities in cell membrane metabolism or 
secondary messenger pathways. In our study, the 
patients were in the euthymic state, and they were taking 
mood-regulating drugs and/or atypical antipsychotics 
and antidepressants. However, medial prefrontal cortical 
neurochemical metabolite levels were found to be lower 
than in controls. Our study supports the hypothesis that 
illness duration and Cho levels are related. As illness 
duration increases, so do abnormalities in membrane 
phospholipid metabolism. 
 
A limitation of our study is the small number of patients. 
The other limitation in our study is that all participants 
used psychotropic drugs, particularly atypical 
antipsychotic and mood-regulating drugs, and these 
drugs are likely to have caused neurochemical changes 
in the brain. In our study, left medial prefrontal cortical 
Cr values were found to be significantly lower in 
patients who used lithium compared with those who did 
not. No differences were detected in other 
neurochemical metabolites. However, the small number 
of patients and their use of multiple drugs might have 
affected our results. It has been reported that lithium 
affects neurochemical metabolite levels, has 
neuroprotective and neurotrophic properties, and 
increases mitochondrial functioning[16, 40-41]. However, 
another study failed to establish a relationship between 
lithium treatment and neurochemical metabolite levels[8]. 
There are conflicting results on valproate usage; while it 
has been claimed that valproate positively affects 
neurochemical metabolite levels and has 
neuroprotective effects[42], others have found that the 
drug does not affect neurochemical metabolites[14]. 
Özdel O, et al. / Neural Regeneration Research. 2012;7(36):2929-2936. 
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Despite the conflicting evidence, it is highly probable 
that psychotropic drugs affect neurochemical 
metabolites. It is very difficult to find bipolar disorder 
patients who do not use medications. More studies are 
required to clarify the effects of drugs on neurochemical 
metabolites. 
 
Yildiz-Yesiloglu and Ankerst[2] reviewed studies 
performed in this field between 1978 and 2005. They 
determined that during euthymic periods, NAA levels in 
bipolar disorder patients are low in frontal structures and 
the hippocampus, and that lithium increases NAA levels. 
Although Cho changes were also reported, the findings 
were not consistent. It is thought that neurochemical 
changes in fronto-limbic-subcortical circuits may play a 
role in the pathophysiology of bipolar disorder. There are 
also putative abnormalities in cell membrane 
phospholipid metabolism, cell energy metabolism, and 
myelin production/maintenance in the frontal cortex, 
cingulate cortex, hippocampus and basal ganglia. We 
previously reported that dorsolateral prefrontal cortical 
NAA levels in bipolar disorder, schizoaffective disorder 
and schizophrenia patients were low compared with 
healthy controls. However, decreased Cho and Cr levels 
were only detected in bipolar disorder and 
schizoaffective disorder, and it was concluded that this 
result could be because of the affective properties of 
both illnesses[43]. 
 
In our study, medial prefrontal cortical NAA, Cho and Cr 
levels were found to be lower in bipolar disorder patients 
compared with healthy controls, but no differences were 
detected in NAA/Cr or NAA/Cho levels. Our results 
suggest that in euthymic bipolar disorder patients, there 
are neurochemical abnormalities in the medial prefrontal 
cortex, impairing neuronal activity and integrity, and that 
there are abnormalities in cellular energy and membrane 
phospholipid metabolism. Our findings need confirmation 
in a larger patient population and long-term studies. 
Studies directed at the relationship between these 
neurochemical changes and mood symptoms, social 
behavior and functionality are needed. 
 
 
SUBJECTS AND METHODS 
 
Design 
A case-control study. 
 
Time and setting 
This study was performed in the Department of 
Psychiatry, Faculty of Medicine, Pamukkale University, 
Turkey between May 2008 and May 2009. 
 
Subjects 
Fifteen healthy controls and 15 patients who were 
diagnosed with type I bipolar disorder according to the 
Diagnostic and Statistical Mental Disorders Manual, 
Fourth Edition [1] were included in the study. Patients with 
bipolar disorder, 18–60 years old, who had not had a 
mood episode in the preceding 3 months, were informed 
about the study. The control group was composed of 
physically and mentally healthy individuals whose age 
and gender were similar to those of the patient group. 
Members of the control group were invited to participate 
via announcements on the bulletin boards of the hospital. 
After being informed about the purpose of the study and 
after undergoing psychiatric evaluation, patients and 
healthy volunteers were included in the study. The study 
was performed in accordance with the Declaration of 
Helsinki [44]. 
 
Exclusion criteria for patients with bipolar disorder and 
healthy controls: (1) mental retardation; (2) alcohol or 
substance use; (3) electroconvulsive therapy in the 




Collection of clinical data 
We prepared a data form that contained sociodemographic 
data and information about the clinical features of the 
illness and applied it to the study participants. The 
Hamilton Depression Rating Scale[45-46] and the Young 
Mania Rating Scale[47-48] were applied to bipolar disorder 
patients. Patients and controls underwent a bilateral 
1H-MRS scan of the medial prefrontal cortex region. 
 
1H-MRS 
1H-MRS scans were performed with a 1.5-Tesla magnetic 
resonance instrument (GE Medical Systems, Milwaukee, 
WI, USA) using a standard head coil. The magnetic 
resonance protocol employed a T2-weighted fast spin 
echo sequence with 10-mm-thickness of the coronal plane 
using repetition time/echo time = 3 000/85; field of view = 
14; matrix = 352 × 352. Single voxel (1H-voxel) magnetic 
resonance spectroscopy was used to analyze the bilateral 
medial prefrontal cortex region (Figures 1 and 2). 
 
The volume of interest being analyzed was manually and 
visually placed in the relevant regions to ensure that it 
covered the relevant frontal lobe areas. The chemical- 
shift-selective pulse technique[49] was used to suppress 
signals originating from water.  













































Subsequently, we employed the point-resolved 
spectroscopy technique[50], which localizes spectroscopy 
volume (repetition time/echo time = 3 000/14 and 35). As 
a result, short and medium duration repetition time 
spectra were obtained inside the volume of interest in 
both medial prefrontal cortex regions, and these data 
were evaluated using GE spectral analysis software. 
Values for NAA/Cr and Cho/Cr were calculated from the 
obtained metabolite values.  
Statistical analysis 
Statistical analysis was performed using SPSS 17.0 
software (Statistical Packages for the Social Sciences, 
Chicago, IL, USA). Conformity of the variables to normal 
distribution was assessed with the Kolmogorov-Smirnov 
goodness-of-fit test. Because of the small number of 
subjects, the variables were not normally distributed, and 
nonparametric statistical techniques were used. 
Differences between measurable values between groups 
were analyzed using the Mann-Whitney U test. 
Relationships between neurochemical metabolite levels 
and illness duration and the number of attacks were 
evaluated using Spearman’s rank-order correlation.  
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